Prolysis and Essential Science extend collaboration

Prolysis, a company that discovers and developments novel antibiotics, and Essential Science, a technology exploitation company, have extended their collaboration focused on the commercialisation of Prolysis' novel bacterial cell biology expertise and antibiotic development programmes.

In the year since Essential Science began working with Prolysis, much progress has been made in establishing Prolysis' profile in the anti-infectives sector. This culminated most recently in the validation of Prolysis' approach through an investment from the corporate investment fund of the Japanese pharmaceutical company Astellas. The extended relationship will now focuses on further exploration of opportunities to out-license Prolysis' proprietary research technologies and development programmes or in-license promising development candidates.

Commenting on the extended collaboration, Steve Ruston ceo of Prolysis said: 'Essential Science made an invaluable contribution to achieving our corporate objectives during the last year. For the future, we are eager to capitalise on the licensing potential of our programmes and technology on an international basis.'

For Essential Science, Neil Murray, CEO, commented: 'The collaboration with Prolysis over the last year has been a rewarding experience for Essential Science and we believe that our joint success confirms the business model of both organisations. We look forward to continuing to provide a long term strategic approach to achieving Prolysis' commercial needs.'